<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318652</url>
  </required_header>
  <id_info>
    <org_study_id>32399/09/18</org_study_id>
    <nct_id>NCT04318652</nct_id>
  </id_info>
  <brief_title>OCT Guided Punctal Stenosis Management</brief_title>
  <official_title>The Role of Anterior Segment Optical Coherence Tomography in Management of Acquired Punctal Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial study that was conducted on patients with punctal stenosis.We
      studied the diameter of stenosed puncta before and after treatment with preserved free
      steroid eye drops using AS-OCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted on 40 eyes of 24 patients have acquired inflammatory punctal stenosis
      and 20 eyes of 10 patients of normal asymptomatic subjects as control group. We studied the
      external punctal diameter, visibility of the internal punctum and punctal depth before
      treatment using AS-OCT, and then patients were re-evaluated after one month of treatment with
      preservative free methylprednisolone 5% eye drops.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2018</start_date>
  <completion_date type="Actual">September 20, 2019</completion_date>
  <primary_completion_date type="Actual">September 5, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>punctal opening</measure>
    <time_frame>one month</time_frame>
    <description>evaluation of punctalopening by OCT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Epiphora Due to Insufficient Drainage</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone eye drops</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Preservative free steroids methylprednisolone 5% eye drops (prepared by dilution of methyleprednisolone 500mg in 10 ml distilled water (Solu-Medrol, Pfizer company) was prepared and given for all enrolled cases by the following regimen 5 times/day for 5 days with gradual decrease every third day over the following 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>distilled water eyedrops</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Distilled water eyedrops instilled 3 times per day for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone eyedrops</intervention_name>
    <description>instillation of methylprednisolone eye drops</description>
    <arm_group_label>Methylprednisolone eye drops</arm_group_label>
    <arm_group_label>distilled water eyedrops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have acquired inflammatory punctum stenosis complaining of epiphora of
             different etiologies.

        Exclusion Criteria:

          -  Previous lacrimal surgery.

          -  Lid margin malposition such as ectropion, entropion or lid retraction.

          -  Medial lid masses obscuring punctum.

          -  History of ocular trauma involving lid margin or punctum.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Amr Awara</name>
      <address>
        <city>Tanta</city>
        <state>Gharbeyia</state>
        <zip>3111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Amr Mahmoud Awara</investigator_full_name>
    <investigator_title>assistant professor of ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacrimal Apparatus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

